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ABSTRACT | Transcutaneous electric nerve stimulation 
is a noninvasive method used in clinical Physiotherapy to 
control acute or chronic pain. Different theories have been 
proposed to explain the mechanism of the analgesic action 
of transcutaneous electric nerve stimulation, as the partici-
pation of central and peripheral neurotransmitters. The aim 
of this study was to evaluate the involvement of noradren-
ergic pathway and of the receptors alfa-2 and beta in the 
modulation of analgesia produced by transcutaneous elec-
tric nerve stimulation of high and low frequency in Wistar 
rats after chronic treatment with propranolol or yohimbine 
intraperitoneally. Animals weighing 200 to 300 g were 
divided into 9 groups (n=8), which were obtained nocicep-
tive thresholds through the Tail Flick before and after applica-
tion of TENS for comparing the change of pain. The admin-
istration of yohimbine or propranolol at a dose of 3 mg/kg 
was effective in antagonizing the analgesia induced by high 
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(150 Hz) and low (10 Hz) frequency transcutaneous elec-
tric nerve stimulation according to ANOVA test followed 
by Duncan post hoc test (p<0.05). Thus, it is suggested the 
involvement of alpha-2 and beta noradrenergic receptors 
in the modulation of transcutaneous electric nerve stimu-
lation-induced analgesia. 
Keywords | Pain; Yohimbine; Propranolol/therapeutic use; 
Transcutaneous Electric Nerve Stimulation; Rats, Wistar.
RESUMO | Estimulação elétrica nervosa transcutânea é um 
método não invasivo utilizado na clínica de Fisioterapia para 
controlar dores aguda ou crônica. Diferentes teorias são pro-
postas para explicar o mecanismo de ação analgésica da estim-
ulação elétrica nervosa transcutânea, como a participação de 
neurotransmissores centrais e periféricos. O objetivo do pre-
sente estudo foi avaliar a participação da via noradrenérgica 
e dos receptores alfa-2 e beta na modulação da analgesia 
DOI: 10.590/1809-2950/35921032014
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INTRODUCTION
Pain is present in all the vital cycle of human beings. Lead 
by great scientific curiosity, it spans psychic and somatic 
aspects. Although unpleasant and stressful1, it acts as a 
protection for the organism2. However, when its vital pro-
tection functions are surpassed, it may seriously compro-
mise quality of life, and bring damages to daily activities3.
Transmission of the painful stimulus as well as its 
inhibition involves multiple mechanisms4. Pain sensa-
tion may be modified by pain inhibitory endogenous sys-
tems, predominantly through the descending pathways of 
noradrenaline, serotonin, and endogenous opioids4,5. The 
locus coeruleus, an important nucleus of the noradrenergic 
brainstem, is involved in the descending control of noci-
ceptive pathways6,7. Catecholamine receptors are classi-
cally divided into two main categories: alpha and beta 
adrenoceptors, and the nociceptive effect of noradrenaline 
is mainly mediated by alpha-2-adrenoceptors4,8.
Many techniques have been used, alone or in asso-
ciation with medicine, to provide analgesia to the 
patient, such as the low-level laser therapy9, acupunc-
ture10, and transcutaneous electrical nerve stimulation 
(TENS)11. TENS is a non-pharmacological, noninva-
sive, of easy use and relatively few counter-indications 
resource that is already known in the modulation of 
acute and chronic pain4,12,13.
Among the countless resources used, TENS and 
its chemical components of the human body like nor-
adrenaline may be an important new mean to relieve 
very intense and frequent pains, providing an improve-
ment in patients’ quality of life. Studies about the rela-
tion between TENS and adrenergic receptors14-17 are 
rare and contradictory. 
The present paper aimed at assessing the participa-
tion of the noradrenergic pathway and its respective 
receptors — alpha-2 and beta — in the modulation of 
analgesia induced by TENS in Wistar rats after treat-
ment through the intraperitoneal pathway (IP) with 
yohimbine (alpha-2-receptor antagonist) and propanol 
(beta-receptor antagonist).
METHODOLOGY
Animals
Rats from the Wistar line that weighed 200 to 300 g, 
originated from the vivarium, were used. The animals 
were grouped in numbers of four inside the polypropyl-
ene boxes, exposed to a 12-hour light-dark cycle with 
a mean temperature of 22 to 24oC; they also had free 
access to food (“Nuvilab” rat food) and water throughout 
induzida pela estimulação elétrica nervosa transcutânea de alta 
e baixa frequência em ratos Wistar, após tratamento crônico com 
ioimbina ou propranolol por via intraperitoneal. Animais pesando 
entre 200 e 300 g foram divididos em 9 grupos (n=8), dos quais 
se obteve os limiares nociceptivos por meio do Tail Flick antes e 
após a aplicação da estimulação elétrica nervosa transcutânea 
para comparação de mudança do quadro álgico. A administração 
de ioimbina ou de propranolol na dose de 3 mg/kg foi efetiva em 
causar uma antagonização da analgesia induzida pela estimulação 
elétrica nervosa transcutânea de alta (150 Hz) e baixa frequência 
(10 Hz) segundo teste ANOVA seguido do teste post hoc Duncan 
(p<0,05). Dessa forma, sugere-se o envolvimento de receptores 
noradrenérgicos alfa-2 e beta na modulação da analgesia induzida 
pela estimulação elétrica nervosa transcutânea. 
Descritores | Dor; Ioimbina; Propranolol/uso terapêutico; 
Estimulação Elétrica Nervosa Transcutânea; Ratos Wistar.
RESUMEN | La estimulación eléctrica nerviosa transcutánea es un 
método no invasivo utilizado en la clínica de Fisioterapia para controlar 
el dolor agudo y crónico. Diversas teorías son propuestas para expla-
nar el mecanismo de acción analgésico de la estimulación eléctrica 
nerviosa transcutánea, como la participación de neurotransmisores 
centrales y periféricos. El objetivo del presente estudio fue evaluar 
la participación de la vía noradrenérgica y de los receptores alfa-2 
y beta en la modulación de analgesia inducida por la estimulación 
eléctrica nerviosa transcutánea con alta y baja frecuencia en ratos 
del tipo Wistar, después del tratamiento crónico con yohimbina o 
propranolol por la vía intraperitoneal. Animales que pesaban 200 y 
300 g fueron divididos en nueve grupos (n=8), por los cuales fueron 
obtenidos los umbrales nociceptivos por medio del Tail Flick, antes 
y después de la aplicación de la estimulación eléctrica nerviosa 
transcutánea con el intuito de comparar la alteración del cuadro 
álgico. La administración de yohimbina o propranolol en el dosis 
de 3 mg/kg fue eficaz en resultar en una antagonización de anal-
gesia inducida por la estimulación eléctrica nerviosa transcutánea 
con alta (150 Hz) y baja (10 Hz) frecuencia, de acuerdo al test de 
ANOVA seguido del test post-hoc de Duncan (p>0,05). Por lo tanto, 
se sugiere el envolvimiento de los receptores noradrenergicos alfa-2 
y beta en la modulación de analgesia inducida por la estimulación 
eléctrica nerviosa transcutánea.
Palabras clave | Dolor; Yohimbina; Propranolol/uso terapéutico; 
Estimulación Eléctrica Nerviosa Transcutánea; Ratos Wistar.
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the experimental period. After the end of experiments, 
the animals were sacrificed with lethal injection of xyla-
zine chloride and ketamine (100 and 375 mg/kg respec-
tively). All experiments were performed following the 
ethical principles of the Ethics Commission in Animal 
Experimentation and following those adopted by the 
Brazilian College of Animal Experimentation – COBEA 
(approval protocol number 08/2009).
Animals were divided into nine groups (n=8). Control 
Groups (1) and (2) – treated with 0.9% physiological 
saline solution (NaCl), low and high frequency TENS 
respectively; Experimental Groups (3) and (4)  – 
treated with alpha-2a antagonist medicine, concomi-
tantly with low and high frequency TENS; Groups (5) 
and (6) – treated with beta antagonist, concomitantly 
low and high frequency TENS; Placebo Groups (7), 
(8) and (9) – treated with 0.9% physiological saline 
(NaCl) and antagonist drugs, both without TENS for 
purposes of intrinsic evaluation of the drug effects on 
the noradrenergic pathway.
Drugs used
Yohimbine (Tocris) and propranolol (Tocris) dissolved in 
physiological saline solution (NaCl at 0.9%) were used. 
Selective (yohimbine) and non-selective (propranolol) 
antagonists of noradrenergic receptors were administered 
through IP pathway in 3 mg/kg doses7,18,19.
TENS
For induction of the antinociceptive status, the TENS 
Vif 993 DUAL (QUARK) equipment was used at low 
(10 Hz) and high frequencies (150 Hz), with initial 
amplitude of 15 mA, varying every five minutes (5 mA); 
and final one of 40 mA, average of 30 minutes of electri-
cal therapy and 1 ms pulse duration. A pair of adhesive 
electrodes was fixed in the distal and proximal regions 
of the animal’s tail, built specially for stimulation, and 
sized around 1 cm2. Animals were calm with the elec-
trodes fixed in their tails during TENS, which could not 
provide a muscular contraction or stressful stimulation 
that would provoke the animal’s scape.
Nociceptive test – Hyperalgesia Measuring
Animals of each group had their nociceptive thresholds 
measured with the use of tail removal test. Every animal 
was put inside a contention cage with acrylic walls and 
their tails put on the sensor of a heating source (tail-
flick – Analgesia Instrument; Stoelting), whose progres-
sive raise was automatically interrupted as soon as the 
animal removed its tail from the equipment. A small 
adjustment of amplitude and current was performed 
whenever necessary, in the beginning of the experiment, 
with the aim of achieving three consecutive latencies of 
tail removal (LTR), between 2.5 to 3.5 seconds. These 
adjustments were done to increase or decrease the level 
of resistance heat of Tail-flick so that the reflex would 
be between 2.5 and 3.5 seconds.
Experimental protocol
Twenty-four hours after determination of baseline for 
the tail removal test, independent groups of Wistar rats 
had been previously treated with only one administration 
of physiological saline (Groups 1 and 2); alpha-2 norad-
renergic antagonist (Groups 3 and 4) or beta (Groups 5 
and 6) in the dose of 3 mg/kg through IP pathway for 
15 consecutive days.
After 10 minutes of the last administration of nor-
adrenergic antagonist or physiological saline that hap-
pened in the 15th day, animals were treated with low or 
high frequency TENS for 30 minutes, and analgesia test 
for LTR was performed at 0, 5, 10, 15, 20, 25, 30, 35, 40, 
45, 50, 55, and 60 minutes.
With the aim of assessing drugs effect (yohim-
bine and propranolol) on the nociceptive threshold, 
Groups 7, 8 and 9 took the same amount of physi-
ological saline of noradrenergic antagonists for the 
same time period; however, they did not take part in 
the electric therapy, remained for 30 minutes only 
with the electrodes of TENS on the tail and device 
off (TENS OFF), right after their thresholds were 
measured in the same time mentioned.
Statistical analysis
For data analysis, the Statistical Package for the Social 
Sciences (SPSS) software, version 14.0, was used. 
Shapiro-Wilk’s test was applied to verify normality 
of data, which followed a normal distribution. Results 
were statistically analyzed in absolute values of the 
respective arithmetic means and standard deviation 
through the analysis of variance (one-way ANOVA) 
and Duncan post-hoc test, in order to find possible 
differences between the groups. The significance level 
adopted in the study was p<0.05.
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RESULTS
Early treatment with yohimbine or propranolol through 
the IP pathway provided an antagonization of analge-
sia induced by TENS, both of high and low frequencies.
ANOVA of repeated measures showed a statistically 
significant effect between the yohimbine or propranolol 
treatments in the IP 3 mg/kg dose associated with 150 Hz 
TENS compared to the group treated with physiologi-
cal saline at 0.9% 0.2 mL/kg IP associated with 150 Hz 
TENS [F(2,16)= 0.806 to 7.876; p<0.005]. The antinoci-
ception seen after applying 150 Hz TENS in the group 
pre-treated with physiological saline remained from 0 to 
60 minutes (Figure 1).
The same findings were seen with low frequency TENS. 
ANOVA showed statistical difference between the yohim-
bine or propranolol treatments in the 3 mg/kg IP dose asso-
ciated with 10 Hz TENS compared to the group treated 
with physiological saline at 0.9% 0.2 mL/kg IP associ-
ated with 10 Hz TENS [F(2,16)=0.806 to 7.876; p<0.005]. 
Antinociception seen after using 10 Hz TENS in the 
group pre-treated with physiological saline also remained 
from 0 to 60 minutes (Figure 2).
Duncan post-hoc test showed a statistic difference 
between the group treated with yohimbine and the one 
treated with propranolol with 150 Hz TENS at 25, 30, 
35, 45, 50, 55, and 60 minutes (p<0.05) (Figure 1).
Duncan post-hoc test showed a statistic difference 
between the group treated with yohimbine and the other 
treated with propranolol with 10 Hz TENS at 40, 45 and 
50 minutes (p<0.05) (Figure 2).
Figure 3 illustrates the absence of effects of the pre-treat-
ment with yohimbine or propranolol in the 3.0 mg/kg dose 
on the nociceptive threshold. ANOVA of one pathway 
(one-way ANOVA) did not show a statistically sig-
nificant effect [F(3,27)= 0.38; p<0.05]. Duncan post-hoc 
test showed absence of significance between the groups 
(p>0.05) (Figure 3).
DISCUSSION
This paper evaluated the noradrenergic participation 
in analgesia induced by TENS in laboratory animals. 
Several and different supraspinal descending inhibitory 
systems were identified as able to modulate the spinal 
nociceptive transmission. With the ongoing investigation, 
places that were limited to structures of the mean line 
of mesencephalon and medulla increased. Recently, it is 
known that the solitary nucleus, locus coeruleus — sub-
coeruleus and the lateral reticular nucleus have a role 
in the modulation of spinal nociceptive transmission6. 
There are some evidences that injuries of an important 
origin of such pathways, the locus coeruleus, depress 
the persistent analgesia that follows tonic-clonic sei-
zures, an effect that also seemed to depend on the par-
ticipation of noradrenergic alpha- and beta-receptors7. 
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Points represent the means of nociceptive thresholds measured in the different times; bars represent EPM. Nociceptive threshold, y axis, time (s). (*) Statistically significant effect (p<0.05) compared to the 
group pre-treated with physiological saline at 0.9% 0.2 mL/kg IP + TENS 150 Hz. (+) Statistically significant effect (p<0.05) compared to the groups pre-treated with yohimbine 3 mg/kg IP + TENS 150 Hz 
according to Duncan post-hoc test
Figure 1. Temporal course of the yohimbine and propranolol injection effect in the 3 mg/kg dose through intraperitoneal pathway (IP) on the nociceptive 
threshold, here represented by tail removal latency
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Noradrenergic cells are highly distributed into the mes-
encephalon and a substantial number of their neurons 
is in the locus coeruleus and has a significant descend-
ing projection to the spinal medulla5,6,20. It might be a 
possibility that the present results about antinocicep-
tion induced by TENS have as their neural basis the 
noradrenergic pathway that was originated in the locus 
coeruleus, an important relay of the endogenous system 
of pain inhibition and of alpha-2 and beta noradrener-
gic receptors. Results found support in recent findings, 
which also suggest that alpha and beta-adrenergic 
receptors participate of the modulation of analgesia21-23.
Yohimbine, a drug that is commonly used for the 
antagonism of alpha-2 noradrenergic receptors7,8,17,24,25, is 
a potent and selective alpha-2 adrenergic receptor antag-
onist22. Yohimbine injections in the dorsal horn of the 
spinal medulla resulted in antagonization of the antino-
ciceptive effect of the stimulation applied in the periaq-
ueductal gray substance26. This report suggests that not 
only noradrenergic receptors of locus coeruleus, but also 
Points represent the means of nociceptive thresholds measured in the different times; bars represent EPM. Nociceptive threshold, y axis, time (s). (*) Statistically significant effect (p<0.05) compared to 
the group pre-treated with physiological saline at 0.9% 0.2 mL/kg IP + TENS 10 Hz. (+) Statistically significant effect (p<0.05) compared to the groups pre-treated with yohimbine 3 mg/kg IP + TENS 10 Hz 
according to Duncan post-hoc test
Figure 2. Temporal course of the yohimbine and propranolol injection effect in the 3 mg/kg dose through intraperitoneal pathway (IP) on the nociceptive 
threshold, here represented by tail removal latency 
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Figure 3. Temporal course of effect absence of yohimbine and propranolol antagonists administered at 3 mg/kg through intraperitoneal pathway (IP) on 
the nociceptive thresholds
0
2
4
6
8
BL1 BL2 BL3 0 5 10 15 20 25 30 35 40 45 50 55 60
Time (minutes)
Propranolol 3mg/kg IP + TENS (o)
Yohimbine 3mg/kg IP + TENS (o)
Physiological saline 0,9% IP + TENS (o)
N
o
ci
ce
p
tiv
e 
th
re
sh
o
ld
   
  
207
Vasconcellos et al. Noradrenergic pathway in analgesia induced by TENS
of the dorsal horn of the spinal medulla may be involved 
in the antinociceptive processes.
It has been demonstrated that, depending on the 
dose, some alpha-noradrenergic receptor antagonists 
present local anesthetic effect27. Propranolol is the drug 
chosen in several studies for the antagonism of beta 
noradrenergic receptors7,23,28,29. It is accepted that, in 
addition to its classical non-selective antagonist action 
on beta-noradrenergic receptors, propranolol inhibits 
ionic currents of high and low tension activated by 
Ca2++ in low concentrations30 and, in higher concen-
trations, it moderately suppresses potassium currents31. 
Nevertheless, in the present study, we considered that 
the propranolol effects happened due to their classi-
cal antagonist action on beta-noradrenergic receptors, 
taking into consideration that propranolol manage-
ment in the doses used in the present study did not 
change the basal nociceptive thresholds achieved by 
means of the tail removal test.
Some theories are proposed to explain TENS action 
mechanism4,17. In 1965, Melzack and Wall suggested the 
existence of a kind of flood-gate in the medulla dorsal 
horn. According to this theory, some neurons would 
have the ability of suppressing the transmission of the 
painful signal of medulla dorsal horn, therefore clos-
ing a hypothetical gate and inhibiting the passage of a 
painful impulse (Spinal Flood-gate Theory)4,32. Spinal 
and supraspinal mechanisms related to neurotransmit-
ters and their receptors are involved in the mechanism 
of analgesia induced by TENS4,17. Recent data support 
this theory, both for the low and for the high frequency 
of TENS33. Muscarinic and serotonergic receptors, and 
opioids are activated by TENS in the spinal medulla and 
brainstem; peripherally, in the places of TENS applica-
tion, alpha-2 noradrenergic receptors and opioids are 
involved in the analgesia induced by TENS14,34.
TENS effects of high and low frequency were seen 
in mutant rats that deprived alpha-2 adrenergic recep-
tor. Analgesia induced by TENS both of high and low 
frequency was reduced in these animals compared to 
controls. Furthermore, a selective antagonist of the 
alpha-2 receptor (SK&F 86466) was intra-articularly 
administered, therefore analgesia induced by TENS was 
reversed; however, this result was not seen in intrathe-
cal and intracerebroventricular administrations. Data 
suggest that alpha-2-receptor has some contribution 
for TENS antihyperalgesia. This result is in agree-
ment with anatomic observations about the localiza-
tion of alpha-2-receptors in primary afferent neurons 
and macrophages next to the injured places14,15. Non-
involvement of spinal alpha-2 noradrenergic recep-
tors in the analgesia of low and high frequency TENS 
was also verified through intrathecal administration of 
yohimbine in Radhakrishnan et al.17 study. Spinal sero-
toninergic receptors participated of the antihyperalgic 
TENS process of low, but not of the high frequency 
one17. In the present study, involvement of alpha-2 and 
beta noradrenergic receptors in the analgesia caused by 
TENS may have happened due to IP administration of 
antagonists. This method was chosen for allowing an 
initial and systemic verification of the participation of 
alpha-2 and beta receptors in the modulation of noci-
ceptive thresholds, since medicine used in this study 
are able to surpass the hematoencephalic obstruction, 
thus acting peripherally and centrally, and being used 
in studies on the antinociceptive process18,19,35.
Present results demonstrate involvement of alpha-2 
and beta noradrenergic receptors after IP administra-
tion of specific antagonists in the antinociceptive process 
induced by TENS. These findings allow us to suggest that 
electric therapy performed by TENS may be harmed due 
to the use of noradrenergic antagonists.
CONCLUSION
It might be possible that noradrenergic pathway and 
alpha-2 and beta-receptors participate of the analgesia 
modulation induced by TENS, since the administra-
tion of yohimbine or propranolol through IP provided 
a reduction of the nociceptive thresholds with electrical 
stimulation in high or low frequency.
REFERENCES
1.  Guimarães SS. Pelos meandros da dor. Mente e cérebro. 
2008;16(188):36-55.
2.  Novaes LHM. A dor: presença e papel no psiquismo humano. Rev 
Dor. 2007;8(2):981-2. 
3.  Dias S. A versão biológica da dor. Com Ciência [Revista Eletrônica 
de Jornalismo Científico] 2007 [citado 24 ago. 2012] Disponível em: 
http://www.comciencia.br/comciencia/?section=8&edicao=24&id=274 
4.  Santos CMF. Estudo da estimulação elétrica nervosa transcutânea 
na nocicepção e no edema induzidos pela administração de 
serotonina intradérmica [dissertação]. Minas Gerais: Escola de 
Educação Física, Fisioterapia e Terapia Ocupacional, Universidade 
Federal de Minas Gerais; 2010.
208
 Fisioter Pesq. 2014;21(3)202-208
5.  Yoshimura M, Furue H. Mechanisms for the anti-nociceptive actions 
of the descending noradrenergic and serotoninergic systems in the 
spinal cord. J Pharmacol Sci. 2006;101(2):107-17.
6.  Jones SL. Descending noradrenergic influences on pain. Prog Brain 
Res. 1991;88:381-94.
7.  Felippotti TT, dos Reis Ferreira CM, de Freitas RL, de Oliveira RC, 
de Oliveira R, Paschoalin-Maurin T, et al. Paradoxical effect of 
noradrenaline-mediated neurotransmission in the antinociceptive 
phenomenon that accompanies tonic-clonic seizures: role of locus 
coeruleus neurons and α(2)- and β-noradrenergic receptors. Epilepsy 
Behav. 2011;22(2):165-77. 
8.  Fairbanks CA, Wilcox GL. Moxonidine, a selective α2-adrenergic and 
imidazoline receptor agonist, produces spinal antinociception in 
mice. J Pharmacol Exp Ther. 1999;290(1):403-12.
9.  Maher CG. Effective physical treatment for chronic low back pain. 
Orthop Clin North Am. 2004;35(1):57-64.
10.  Kim DH, Cho SH, Song KH, Lee SE, Lee SH, Kwon GO, et al. 
Electroacupuncture analgesia for surgery in cattle. Am J Chin Med. 
2004;32(1):131-40.
11.  Kararmaz A, Kaya S, Karaman H, Turhanoglu S. Effect of the frequency 
of transcutaneous electrical nerve stimulation on analgesia during 
extracorporeal shock wave lithotripsy. Urol Res. 2004;32(6):411-5.
12.  Morimoto HC, Yonekura MY, Liebano RE. Estimulação elétrica 
nervosa transcutânea nas modalidades convencional e acupuntura 
na dor induzida pelo frio. Fisioter Pesq. 2009;16(2): 148-54.
13.  Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: 
basic science mechanisms and clinical effectiveness. J Pain. 
2003;4(3):109-21.
14.  DeSantana JM, Walsh DM, Vance C, Rakel BA, Sluka KA. Effectiveness 
of transcutaneous electrical nerve stimulation for treatment of 
hyperalgesia and pain. Curr Rheumatol Rep. 2008;10(6):492-9.
15.  King EW, Audette K, Athman GA, Nguyen HO, Sluka KA, Fairbanks CA. 
Transcutaneous electrical nerve stimulation activates peripherally 
located alpha-2A adrenergic receptors. Pain 2005;115:364-73.
16.  Sluka KA. The Neurobiology of pain and foundations for electrical 
stimulation. In: Robinson AJ; Snyder-Mackler L (eds). Clinical 
Electrophysiology. Philadelphia: Lippincott Williams & Wilkins; 
2008:107-49.
17.  Radhakrishnan R, King EW, Dickman JK, Herold CA, Natalie F. 
Johnston NF, et al. Spinal 5-HT2 and 5-HT3 receptors mediate low, 
but not high, frequency TENS-induced antihyperalgesia in rats. Pain. 
2003;105(1-2):205-13.
18.  Freitas RL, Ferreira CM, Ribeiro SJ, Carvalho AD, Elias-Filho DH, 
Garcia-Cairasco N, et al. Intrinsic neural circuits between dorsal 
midbrain neurons that control fear-induced responses and seizure 
activity and nuclei of the pain inhibitory system elaborating postictal 
antinociceptive processes: a functional neuroanatomical and 
neuropharmacological study. Exp Neurol. 2005;191(2):225-42.
19.  Ferreira CMR. Estudo do envolvimento dos receptores 
noradrenérgicos alfa1, alfa2 e beta do sistema endógeno de inibição 
de dor nas alterações dos limiares nociceptivos induzidas por crises 
convulsivas isoladas e durante a fase silenciosa do status epilepticus e 
no modelo de kindling farmacológico [tese]. Minas Gerais: Faculdade 
de Medicina de Ribeirão Preto, Universidade de São Paulo, 2009.
20.  Pertovaara A. Noradrenergic pain modulation. Progress in 
Neurobiology. 2006;80(2):53-83. 
21.  Kawasaki Y, Kumamoto E, Furue H, Yoshimura M. Alpha 2 
adrenoceptor-mediated presynaptic inhibition of primary afferent 
glutamatergic transmission in rat substantia gelatinosa neurons. 
Anesthesiology. 2003;98(3):682-9.
22. Binder W, Mousa SA, Sitte N, Kaiser M, Stein C, Schäfer M. Sympathetic 
activation triggers endogenous opioid release and analgesia within 
peripheral inflamed tissue. Eur J Neurosci. 2004;20(1):92-100.
23.  Saadé NE, Al Amin HA, Barchini J, Tchachaghian S, Shamaa F, Jabbur 
SJ, et al. Brainstem injection of lidocaine releases the descending 
pain-inhibitory mechanisms in a rat model of mononeuropathy. Exp 
Neurol. 2012;237(1):180-90. 
24.  Lalchandani SG, Lei L, Zheng W, Suni MM, Moore BM, Liggett SB, 
Miller DD, et al. Yohimbine dimers exhibiting selectivity for the 
human alpha 2C-adrenoceptor subtype. J Pharmacol Exp Ther. 
2002;303(3):979-84.
25.  Sahraei H, Ghazzaghi H, Zarrindast MR, Ghoshooni H, Sepehri H, 
Haeri-Rohan A. The role of alpha-adrenoceptor mechanism(s) in 
morphine-induced conditioned place preference in female mice. 
Pharmacol Biochem Behav. 2004;78(1):135-41.
26.  Peng YB, Lin Q, Willis WD. Involvement of alpha-2 adrenoceptors in 
the periaqueductal gray-induced inhibition of dorsal horn cell activity 
in rats. J Pharmacol Exp Ther. 1996;278(1):125-35.
27.  Morales Aguilera A, Vaughan Williams EM. The effects on cardiac 
muscle of beta-receptor antagonists in relation to their activity as 
local anaesthetics. Br J Pharmacol Chemother. 1965;24:332-8.
28.  Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, McLean 
SA, et al. Effect of catechol-O-methyltransferase polymorphism on 
response to propranolol therapy in chronic musculoskeletal pain: a 
randomized, double-blind, placebo-controlled, crossover pilot study. 
Pharmacogenet Genomics. 2010;20(4):239-48.
29.  Park DS, Seo BK, Baek YH. Analgesic effect of electroacupuncture on 
inflammatory pain in collagen-induced arthritis rats: mediation by 
alpha2- and beta-adrenoceptors. Rheumatol Int. 2013;33(2):309-14.
30.  Akaike N, Ito H, Nishi K, Oyama Y. Further analysis of inhibitory effects 
of propranolol and local anaesthetics on the calcium current in Helix 
neurones. Br J Pharmacol. 1982;76(1):37-43.
31.  Akaike N, Nishi K, Oyama Y. Inhibitory effects of propranolol on the 
calcium current of Helix neurones. Br J Pharmacol. 1981;73(2):431-4.
32.  Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 
1965;19;150(3699):971-9.
33.  Sluka KA, Walsh D. Trancutaneous Electrical Nerve Stimulation: 
Basic Science Mechanisms and Clinical Effectiveness. J Pain. 
2003;4(3):109-21.
34.  Sluka KA. The Neurobiology of pain and foundations for electrical 
stimulation. In: Robinson AJ; Snyder-Mackler L, editors. Clinical 
Electrophysiology. Philadelphia: Lippincott Williams & Wilkins; 
2008:107-49.
35.  Marcondes Sari MH, Guerra Souza AC, Gonçalves Rosa S, Souza D, 
Dorneles Rodrigues OE, Wayne Nogueira C. Contribution 
of dopaminergic and adenosinergic systems in the 
antinociceptive effect of p-chloro-selenosteroid. Eur J Pharmacol. 
2014;725(15):79-86.
